Existing atherosclerotic cardiovascular disease (ASCVD) risk calculators appear to be inadequate, noted researchers led by ...

Current cardiac screening tools used to prevent heart attacks fail to identify nearly half of the people who are actually at ...

Around half of study participants, all age 65 or younger, wouldn’t have been eligible for statins if they’d sought care 2 ...

PCSK9 inhibitor therapy is less likely to be utilized in Black, Hispanic, and low-income patients hospitalized with ...

Panel (A) shows classifications based on the ASCVD Risk Estimator Plus, where 45% (209/465) of patients would not have ...

Trials of a new cholesterol-lowering pill have shown promising results for people with heterozygous familial ...

Scribe Therapeutics highlights data underpinning its comprehensive strategy targeting key lipid drivers of ASCVD at AHA Scientific Sessions 2025 ...

Patients with depression may develop atherosclerotic cardiovascular disease earlier and start treatment more often than those ...

Released in 2023, PREVENT is a tool estimating CVD, ASCVD, and heart failure risk over 10 or 30 years for adults as young as ...

When comparing atherosclerotic cardiovascular disease (ASCVD) with cancer, patients with both diseases appeared to have the greatest risk of experiencing financial toxicity. Financial toxicity is ...

Early onset of menopause is an important risk factor for atherosclerotic cardiovascular disease (ASCVD), according to an analysis of women enrolled in numerous population-based studies. “To me, what ...

Once-weekly semaglutide 2.4 mg reduced the risk for major adverse cardiovascular events among adults with overweight or obesity who were at risk for atherosclerotic cardiovascular disease, according ...